A multicentre, randomized, double-blind, placebo-controlled, parallel-design trial of the efficacy and safety of subcutaneous tetrodotoxin (Tectin) for moderate to severe inadequately controlled cancer-related pain.
Phase of Trial: Phase II/III
Latest Information Update: 08 Apr 2008
At a glance
- Drugs Tetrodotoxin (Primary)
- Indications Cancer pain
- Focus Therapeutic Use
- Acronyms TTX
- Sponsors WEX Pharmaceuticals
- 08 Apr 2008 A reanalysis was published in the April 2008 issue of the Journal of Pain and Symptom Management; based on this, a new trial [TEC-006; see 700032511] has been initiated.
- 12 Dec 2005 New trial record.